Celladon Corp Share Price Nasdaq
Equities
US15117E1073
Biotechnology & Medical Research
Sales 2024 * | 25.22M 2.01B | Sales 2025 * | 32.65M 2.6B | Capitalization | 3.98M 318M |
---|---|---|---|---|---|
Net income 2024 * | -24M -1.91B | Net income 2025 * | -9M -717M | EV / Sales 2024 * | 0.16 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.12 x |
P/E ratio 2024 * |
-0.17
x | P/E ratio 2025 * |
-0.75
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.23% |
Latest transcript on Celladon Corp
Managers | Title | Age | Since |
---|---|---|---|
David Apelian
CEO | Chief Executive Officer | 59 | 13/06/17 |
James Vollins
CMP | Compliance Officer | 55 | 12/04/23 |
Colin Hislop
CTO | Chief Tech/Sci/R&D Officer | 66 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 57 | 17/07/22 | |
Thomas Dietz
CHM | Chairman | 60 | 21/03/16 |
David Apelian
CEO | Chief Executive Officer | 59 | 13/06/17 |
1st Jan change | Capi. | |
---|---|---|
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |